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Abstract
Background: Midkine (MK), a member of the heparin-binding growth factor family, which includes MK and 
pleiotrophin, is known to possess neurotrophic and neuroprotective properties in the central nervous system. Previous 
studies have shown that MK is an effective neuroprotective agent in reducing retinal degeneration caused by excessive 
light and decreasing hippocampal neuronal death in ischemic gerbil brain. The present study was undertaken to 
investigate whether MK acts as an anticonvulsant in kainic acid (KA)-induced seizure in mouse and blocks KA-mediated 
neuronal cell death in hippocampus.
Results: Increased expression of MK was found in hippocampus of mouse following seizures induced by 
intracerebroventricular injection of KA, and MK expression was found in glial fibrillary acidic protein (GFAP)-positive 
astrocytes. Concurrent injection of MK and KA attenuated KA-induced seizure activity and cell death of hippocampal 
neurons including pyramidal cells and glutamic acid decarboxylase 67 (GAD67)-positive GABAergic interneurons in the 
CA3 and hilar area.
Conclusion: The results of the present study indicate that MK functions as an anticonvulsant and neuroprotective 
agent in hippocampus during KA-induced seizures.
Background
Temporal lobe epilepsy (TLE) is pathologically character-
ized by extensive neuronal loss in the CA1, CA3 and hilar
regions of hippocampus [1,2]. Previous studies have dem-
onstrated that the animal models of TLE generated by
intracerebroventricular injection of kainic acid (KA) faith-
fully reproduce clinical and pathological features found in
human TLE [3-7].
Previous studies have reported the possible involvement
of neurotrophic factors in epilepsy as suggested by the gene
expression of neurotrophic factors such as NGF, BDNF and
NT-3 in hippocampus in human TLE as well as in TLE ani-
mal models [8,9]. Midkine (MK), one of such neurotrophic
factors, has emerged as an important neuromodulator in the
central nervous system (CNS). MK, a member of the hepa-
rin-binding growth factor family, which includes MK and
pleiotrophin, is known to possess neurotrophic and neuro-
protective properties [10,11]. MK was originally isolated as
the product of retinoic acid-responsive gene that functions
primarily in inducing cell differentiation in mouse terato-
carcinoma cells [12], and has the ability to influence a vari-
ety of neuronal functions including neurite extension [13],
neuronal differentiation [14,15] and neuronal survival fol-
lowing injury or damage in the CNS [15,16]. During the
fetal development of the CNS, MK expression was demon-
strated in neuroepithelial/neural progenitor cells following
ethylnitrosourea injury [17] indicating that MK might have
a role in cellular proliferation [18]. Recent studies further
showed that MK has been implicated in neurological dis-
eases, including Alzheimer's disease [19], cerebral ischemia
[20] and Parkinson-dementia complex of Guam (Lytico-
bodig disease) [21]. In patients with Alzheimer's disease
[19] or Lytico-bodig disease [21], MK immunoreactivity
was found in senile plaques and neurofibrillary tangles. In
addition, an increased expression of MK was found in
astrocytes in rat models of cerebral ischemia [22]. It is not
known, however, whether the expression of MK in the brain
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cess to prevent further damage in the CNS.
The objectives of the present study are to determine
whether intracerebroventricularly injected MK acts as an
anticonvulsant and blocks KA-mediated neuronal cell death
in hippocampus.
Results
MK expression after seizures
We first examined MK expression immunohistochemically
in mouse hippocampus following KA injection. Injection of
KA (0.2 μg/mouse) to mice induced severe epileptiform
seizures (mean score 4.2/maximum score 5.0). Basal level
of MK immunoreactivity was found in hippocampal pyra-
midal neurons in control mouse brain injected with vehicle
[phosphate-buffered saline (PBS)] (Figure 1A, top left
panel), while in mouse injected with KA decreased MK
expression was detected in pyramidal neurons (Figure 1A,
bottom left panel; see arrows); Nissl staining of the adjacent
sections confirmed that the cellular area of decreased MK
immunoreactivity was associated with damaged pyramidal
neurons (Figure 1A, bottom right panel; see arrows). Nissl
staining in control animals receiving PBS injection showed
no evident neuronal damage (Figure 1A, top right panel).
Interestingly, we have found the number of MK-positive
cells markedly increased in stratum lacunosum moleculare
(Slm) area of CA3 at 24-hr post-KA injection relative to
PBS controls. Representative MK immunostaining in CA3
Slm is shown in Figure 1B (box denotes area of high mag-
nification, top panel). In PBS-injected brain, only small
number of MK-positive cells was observed (Figure 1B,
middle panel). Following injection of KA, CA3 Slm area
demonstrated an increase in the number of MK-positive
cells (Figure 1B, bottom panel). Double-labeling immuno-
fluorescence staining was then used to investigate MK
expression in glial cells in KA-injected hippocampus. Rep-
resentative double staining for MK (green staining, Figure
1C top panel) and GFAP (red staining, Figure 1C middle
panel) showed that MK was expressed in GFAP-positive
astrocytes; there was no MK expression in anti-complement
receptor 3 (OX-42)-positive microglia (data not shown).
Quantification of MK expression data (expressed as area
density of MK-positive cells, Figure 2) showed that KA
injection significantly decreased MK immunoreactivity by
44% in SP area relative to PBS-injected control. However,
the MK immunoreactivity in animals with KA injection
markedly increased by 651% in Slm area as compared to
PBS-injected control.
Anticonvulsant effect of MK
To further investigate the role of MK in KA-injected hip-
pocampus, we examined the potential protective effects of
MK against KA-induced seizures and neurotoxicity. Sei-
zure onset was approximately 170 sec following KA injec-
tion, which lasted for mean 1,200 sec (Table 1). The
intensity of seizures reached mean score 4.2 (maximum
score 5.0) when the seizure activity was highest (5-10 min
after KA challenge). Interestingly, seizure duration and
Figure 1 MK expression in the hippocampus after KA injection. 
(A) Representative immunofluorescence images of MK immunoreac-
tivity in hippocampal CA3 pyramidal neurons 24 hr after PBS injection 
(top left panel) or KA (0.2 μg/mouse, bottom left panel). Adjacent hip-
pocampal sections stained with Nissl staining (right panels) are shown 
here. Following KA treatment, cell death in CA3 pyramidal neurons is 
clearly visible (arrows). Scale bars: 20 μm (top panels), 30 μm (bottom 
panels). (B) Representative immunofluorescence images of MK-posi-
tive cells in CA3 Slm (striatum lacunosum moleculare) (box in top pan-
el indicates region of interest) after injection with PBS (middle panel) or 
KA (0.2 μg/mouse, bottom panel). (C) Double-labeling immunofluores-
cence staining of MK (green, top panel) with GFAP (red, middle panel) 
showing MK immunoreactivity is co-localized on GFAP-positive astro-
cytes in CA3 Slm (bottom panel). Scale bar: 20 μm.
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MK in a dose-dependent manner, although the time of onset
time slightly delayed at a high dose (0.4 μg/mouse). Seizure
duration and intensity were shortened and attenuated to
51.4 - 26.5% and 59.5 - 40.5% of the control levels by treat-
ment with KA (0.1 - 0.4 μg/mouse), respectively.
Neuroprotective effect of MK
Representative Nissl staining 24 hr following KA injection
showed considerable neuronal loss in the hippocampal sub-
regions, CA3 and hilus of the dentate gyrus as compared to
PBS control (Figure 3A, left and middle panels). MK treat-
ment was effective in reducing neuronal loss in KA-
injected hippocampus as shown in a representative finding
in a high dose (0.4 μg/mouse) group (Figure 3A, right pan-
els). The extent of degeneration of hippocampal neurons
was quantified in hippocampal subregions, CA1, CA3, and
hilus (Figure 3B). The number of hippocampal neurons was
significantly reduced in CA3 (-81%) and hilus (-85%) by
KA exposure, whereas CA1 region (-19%) was relatively
spared when compared with PBS control. Co-application of
MK increased survival of neurons in KA-injected hip-
pocampus in a dose-dependent manner, leading to signifi-
cant improvements at KA doses of 0.2 and 0.4 μg/mouse.
Next we investigated the efficacy of MK to block the
KA-induced cell death of GABAergic interneurons
(GAD67-positive neurons). A previous study has reported
that GAD67-positive interneurons are lost in the hippocam-
pus in KA-injected animal model of excitotoxicity [23].
Animals receiving KA injection showed significant reduc-
tion in the number of GAD67-positive interneurons in sub-
fields of CA1 (strata oriens -80%, strata pyramidale -64%,
strata radiatum -33%), CA3 (strata oriens -91%, strata pyra-
midale -78%, strata radiatum -62%) and layers of dentate
gyrus (molecular layer -37%, granule cell layer -69%, den-
tate hilus -77%) as compared to PBS control (Figures 4 and
5). Administration of MK (0.4 μg/mouse) reduced the cell
loss in GAD67-positive neurons caused by KA injection
and this neuroprotective effect of MK was evident in the
subfields of CA3 and layers of dentate gyrus (Figure 4).
Application of MK markedly increased survival of GAD67-
positive neurons in the strata pyramidale (68% improve-
ment), radiatum (45% improvement) of CA3 and molecular
layer (27% improvement), granule cell layer (29%
improvement), and dentate hilus (33% improvement) of
dentate gyrus, whereas neurons in subfields of CA1 was not
effectively preserved (Figure 5).
Discussion
The main finding of this study is that intracerebroventricu-
lar administration of MK conferred neuroprotection against
KA-induced excitotoxic cell death of hippocampal neurons.
Our results also demonstrated that MK was effective in
attenuating KA-induced seizures and degeneration of
GABAergic interneurons in hippocampus. The results from
immunohistochemical staining showed that damaged pyra-
midal neurons in hippocampus are correlated with the
decreased level of MK expression (Figure 1A). At present,
it is not known whether this reduced level of MK immuno-
reactivity in neurons is causative factor for neuronal degen-









Vehicle 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
KA (0.2) alone 169.9 ± 38.8* 1,200.6 ± 372.3* 4.2 ± 0.1*
+MK (0.1) 160.0 ± 28.5 616.7 ± 50.3# 2.5 ± 0.3#
+MK (0.2) 172.8 ± 33.8 422.4 ± 71.5# 2.2 ± 0.2#
+MK (0.4) 188.8 ± 47.0 318.6 ± 31.7# 1.7 ± 0.3#
Data are presented as mean ± SEM. * p < 0.05, as compared with PBS. # p < 0.05, as compared with KA. Student's t-test.
Figure 2 Site-selective MK expression in the KA-damaged hip-
pocampus. Bar graph shows the quantification of MK immunoreactiv-
ity in SP (stratum pyramidale) and Slm (stratum lacunosum 
moleculare) of hippocampal CA3 region 24 hr after PBS or KA (0.2 μg/
mouse) injection. Data are presented as mean ± SEM. * p < 0.05, as 
compared with PBS. One-way ANOVA, Student-Newman-Keuls multi-
ple comparison test.
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Figure 3 Effect of MK on hippocampal neuronal damage induced by KA injection. (A) Representative Nissl-stained sections from animals 24 hr 
after PBS (left panels), KA (0.2 μg/mouse, middle panels) or KA plus MK (0.4 μg/mouse, right panels) injection. Top panels shows at low magnification 
of the hippocampus. Scale bar: 400 μm. Middle and bottom panels show at high magnification of CA3 and dentate gyrus (DG) subregions of hip-
pocampus. Scale bars: 200 μm. Note that the damaged areas induced by KA are indicated by absence of Nissl-positive neurons. (B) Quantification of 
undamaged Nissl-positive neurons for the hippocampal subregions CA1 and CA3, and hilus of dentate gyrus with different MK doses (0.1 -- 0.4 μg/
mouse). Data are presented as mean ± SEM. * p < 0.05, as compared with PBS. # p < 0.05, as compared with KA. One-way ANOVA, Student-Newman-
Keuls multiple comparison test.
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studies have demonstrated that MK is an effective neuro-
protective agent in reducing retinal degeneration caused by
excessive light [24] and decreasing hippocampal neuronal
death in ischemic gerbil brain [25]. Furthermore, MK
knock-out mice displayed altered expression of calcium-
binding protein in hippocampus and defective working
memory [26]. In view of these observations, it is possible
that MK is involved in the regulation of endogenous neuro-
protective process against externally applied injury or dis-
ease.
We have found that the level of MK immunoreactivity
markedly increased in astrocytes after KA injection (Figure
1C). In a previous report, we have demonstrated rapid acti-
vation of astrocytes in hippocampal alveus and fimbria,
strata oriens and lacunosum moleculare as well as dentate
hilus as early as 1 hr following diisopropyl fluorophosphate
(DFP)-induced seizures and neuronal injury [27]. These
observations suggest that the activated astrocytes serve as
an important source of MK in response to excitotoxicity.
Important findings in the present study are therapeutic and
neuroprotective effects of MK on KA-induced neuronal
injury in CA3 and dentate hilus of hippocampus (Figure 3).
Our results are in good agreement with a previous study of
neuroprotective effect of MK in transient forebrain isch-
emia when given immediately before middle cerebral artery
occlusion [25]. Previous studies have demonstrated that
KA-injected brain show dramatic reduction in the number
of GAD-positive interneurons [7,23,28], even in CA1
statum oriens and alveus where pyramidal neurons are rela-
tively spared [Figures 3-5][29], which can cause abnormal
functional inhibition of neuronal circuitry leading to hip-
pocampal hyperexcitability [2,7]. Thus, it is noteworthy
that icv application of MK blocks the degeneration of
GAD67-positive interneurons, especially in the stratum
pyramidale and radiatum of CA3, and the molecular layer,
Figure 4 Protective effect of MK on KA-induced cell loss of GAD67-positive GABAergic neurons. Hippocampal coronal sections from animals 
were immunostained with glutamic acid decarboxylase 67 (GAD67) antibody 24 hr after PBS (left panels), KA (0.2 μg/mouse, middle panels), KA plus 
MK (0.4 μg/mouse, right panels) injection. High magnification of representative GAD67-stained images of hippocampal subregions CA1 (top panels), 
CA3 (middle panels), and DG (bottom panels) from different treatments are shown here. Scale bar: 200 μm. Note the paucity of GAD67-positve cells 
in KA-treated CA3 and dentate gyrus subregions.
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Figure 5 Protective effect of MK on KA-induced GABAergic neuronal cell death. Numbers of GAD67+ neurons were counted in subregions of 
hippocampus from PBS, KA (0.2 μg/mouse), and KA plus MK (0.4 μg/mouse)-injected mice; strata oriens (SO), pyramidale (SP) and radiatum (SR) of CA1 
(A) and CA3 (B) and all layers of dentate gyrus (C) (ML; molecular layer, GCL; granule cell layer, DH; dentate hilus). Data are presented as mean ± SEM. 
* p < 0.05, as compared with PBS. # p < 0.05, as compared with KA. One-way ANOVA, Student-Newman-Keuls multiple comparison test.
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KA injection (Figures 4 and 5).
The majority of the animals experienced stage 4/5 seizure
severity after KA injection. A previous study has demon-
strated in KA-injected rat epilepsy model that dizocilpine
(MK-801) inhibited hippocampal neuronal loss without
blocking seizure development [30]. In addition, several
studies in animal model of TLE have also shown that sig-
nificant neuronal loss is not necessarily a prerequisite for
the development of seizures [31,32]. Such results imply that
the mechanism of MK action in TLE model is different
from that of MK-801, an NMDA antagonist. Our results
show that MK-induced neuroprotection against KA toxicity
is primarily associated with moderation of seizure activity
(Table 1). It is believed that MK plays a role as an anticon-
vulsant directly (Table 1) or indirectly by preserving an
inhibitory amino acid (GABA) system including GAD67-
positive interneurons (Figures 4 and 5). Furthermore, it is
possible to speculate that MK could be a neurotrophic fac-
tor, especially for GAD67-positive interneurons or astro-
cytes expressing high levels of MK (Figure 1) which may
contribute to early cessation of seizure and control of its
recurrence.
The exact mechanism of the neuroprotective activity of
MK remains to be further clarified but activation of gene
product(s) associated with apoptosis by MK may provide
some answers. For instance, previous studies have shown
that MK inhibits apoptotic process by up-regulation of bcl-
2 expression [33] and by inhibition of caspase-3 activation
[34]. Thus, it is possible that the MK-mediated neuropro-
tective mechanism involves activation of signal transduc-
tion pathways involved in regulation of apoptotic cell
death.
Conclusions
The results of the present study demonstrate that the admin-
istration of MK produces a significant neuroprotective
effect against KA-induced neuronal loss in mouse model of
epilepsy. Additional studies of MK to elucidate their neuro-
protective activity in animal models of brain injury and
neurodegeneration such as Parkinson's disease, Hunting-
ton's disease, amyotropic lateral sclerosis, stroke or spinal
cord injury should prove MK as a member of neurotrophic
factors that are valuable in providing effective treatment for
patients with various neurological disorders.
Methods
Treatment and seizure monitoring
Male C57BL/6 mice (n = 8/group) weighing 25 - 30 g were
used for the experiments. The animals were housed in a
temperature- and humidity-controlled room that was kept
on an alternating 2-hr light/dark schedule. Food and water
were available ad libitum throughout the experiments. All
animal experiments were conducted in accordance with the
on Animal Care Committee of the University of British
Columbia.
Animals were anesthetized with intraperitoneal injection
of chloral hydrate (7%, 0.1 mL/kg) and then mounted in a
stereotaxic apparatus (David Kopf Instruments, Tujunga,
CA). KA (0.2 μg/0.4 μL PBS/mouse; Sigma, St. Louis,
MO) was injected into the right lateral cerebroventricle at
the coordinate (AP, -2.0; ML, -2.9; DV, -3.8) using a 10 μL
Hamilton syringe fitted with 26G needle at a rate of 0.1 μL/
min. The needle was left in place for 5 min. MK (0.1, 0.2 or
0.4 μg/0.4 μL PBS; LG Biotech, Daejon, Korea) was unilat-
erally co-injected with KA into the right lateral cerebroven-
tricle. For sham-operated animals, the same volume of 0.1
M PBS was stereotaxically injected into the same coordi-
nates described above. Wounds were sutured, and animals
were allowed to recover and then returned to their cages.
After KA injection, each animal was placed in a Plexiglas
cylinder and their seizure behaviors - latency to onset, dura-
tion, and intensity - were recorded for a period of 120 min
in a blind manner. Seizure intensity was scored with a slight
modification from a previous scoring system [35] as fol-
lowed: stage 1, immobilization and staring; stage 2, head
nodding; stage 3, rearing accompanied by forelimb clonus
and wet dog shakes; stage 4, falling and wobbling; stage 5,
jumping, circling, or rolling. The starting time of head nod-
ding was considered onset time of seizures, because the
starting of immobilization and staring behaviors (stage 1)
was not clear.
Immunohistochemistry
The animals were anesthetized and transcardially perfused
with 50 mL cold saline followed by 100 mL of 4% para-
formaldehyde in 0.1 M phosphate buffer (pH 7.4) 24 hr
after KA administration. The brains were removed from the
skull and post-fixed in 4% paraformaldehyde for 24 hr, fol-
lowed with cryoprotection in 30% sucrose in phosphate
buffer for 2 days. Serial coronal sections at 30 μm were pre-
pared on a cryostat (CM 1900; Leica, Heerbrugg, Switzer-
land). Free-floating sections were prepared from the brains
of PBS, KA, and KA plus MK-injected mice. For single
immunofluorescence staining, brain sections were incu-
bated in PBS containing 5% normal goat serum and 0.2%
Triton X-100 for 30 min at room temperature (RT), and
then incubated overnight with rabbit anti-MK antibody
(1:500, kindly provided by Dr. T. Muramatsu, Nagoya Uni-
versity, Japan). Sections were then incubated with Alexa
Fluor 488-conjugated goat anti-rabbit IgG (1:200; Molecu-
lar Probes, Eugene, OR) at RT for 2 hr in the dark. Sections
were washed in phosphate buffer, mounted on slides. Nissl
staining was also performed on slide-mounted brain sec-
tions with 0.1% cresyl violet (Sigma) for the evaluation of
hippocampal neuronal loss.
For GAD67 immunohistochemical staining, all incuba-
tion solutions did not contain Triton X-100. The brain sec-
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min and incubated with 5% normal goat serum for 30 min.
The sections were incubated overnight at 4°C with rabbit
anti-GAD67 (1:1000; Chemicon, Temecula, CA). The sec-
tions were then incubated for 1 hr with biotinylated anti-
rabbit IgG (1:200; Vector, Burlingame, CA), followed by
incubation with avidin-biotin complex (1:200, Vector) for 1
hr and then visualized with 0.05% 3,3'-diaminobenzidine
(Sigma) and 0.003% H2O2. Negative control sections were
prepared for immunohistochemical staining in an identical
manner except the primary antibodies were omitted.
Double-labeling immunofluorescence microscopy
Free floating sections were incubated in PBS containing 3%
normal goat serum and 0.3% Triton X-100 for 30 min at
room temperature (RT). Brain sections were incubated for
48 hr at 4°C in a mixture of two primary antibodies: MK
(1:100) in combination with mouse anti-GFAP (1:500;
Sigma) or mouse OX-42 (1:200; Serotec, Oxford, UK).
Sections were then incubated in a mixture of Alexa Fluor
488-conjugated goat anti-rabbit IgG (1:200; Molecular
Probes) and Alexa Fluor 594-conjugated goat anti-mouse
IgG (1:200; Molecular Probes) at RT for 2 hr in the dark.
Processed sections were mounted on gelatin-coated slides,
coversliped and examined under a Zeiss Axioplan-2 micro-
scope.
Quantitative analysis
Five coronal hippocampal sections (at the level of the injec-
tion site and spaced 60 μm from each other) were used for
immunohistochemical analysis. All quantitative analyses
were performed in a blind manner. To ensure consistency in
tissue sampling, matched hippocampal sections (based on
anatomical landmark) were always processed throughout
the experiments. Digitized images of stained sections were
acquired using a Zeiss Axioplan-2 microscope equipped
with a DVC camera (Diagnostic Instruments, Sterling
Heights, MI). These images were then analyzed using
Northern Eclipse software (Empix Imaging, Mississauga,
ON, Canada). Three microscopic fields within SP (stratum
pyramidale) and Slm (stratum lacunosum moleculare) areas
in CA3 were selected (magnification of ×40) in MK-stained
sections. MK immunoreactivity was then measured and
expressed as area density of MK (the fraction of the total
given area occupied by MK-positive cells). Three micro-
scopic fields (magnification at ×40) in CA1, CA3 and hilus
region were counted for Nissl-stained undamaged neurons
in each coronal brain section. Neurons are identified by
dark nucleoli within lightly stained nuclei. GAD67-positive
neurons were quantified in CA1 and CA3 subfields (strata
oriens, radiatum, and pyramidale) and dentate gyrus layers
(dentate hilus, granule cell layer, and molecular layer).
These regions were established according to the atlas of
Paxinos & Watson [36]. Number of Nissl- and GAD67-pos-
itive neurons was expressed as a percentage of the PBS-
injected control sections.
Statistical analysis
Data are presented as means SEM. The statistical signifi-
cance was determined by one-way ANOVA and Student-
Newman-Keuls test or Student's t-test using the StatView
program (Abacus Concepts, Berkeley, CA). p values < 0.05
were considered to be statistically significant.
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